Caxton Associates (New York)’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-18,121
| Closed | -$2.49M | – | 606 |
|
|
2024
Q2 | $2.49M | Sell |
18,121
-407
| -2% | -$56K | 0.09% | 124 |
|
|
2024
Q1 | $2.56M | Buy |
+18,528
| New | +$2.56M | 0.14% | 97 |
|
|
2023
Q1 | – | Sell |
-4,869
| Closed | -$582K | – | 580 |
|
|
2022
Q4 | $582K | Buy |
4,869
+1,874
| +63% | +$224K | 0.04% | 195 |
|
|
2022
Q3 | $318K | Buy |
+2,995
| New | +$318K | 0.04% | 301 |
|
|
2020
Q3 | – | Sell |
-9,510
| Closed | -$1.16M | – | 436 |
|
|
2020
Q2 | $1.16M | Buy |
+9,510
| New | +$1.16M | 0.1% | 51 |
|
|
2020
Q1 | – | Sell |
-4,061
| Closed | -$437K | – | 518 |
|
|
2019
Q4 | $437K | Buy |
+4,061
| New | +$437K | 0.06% | 189 |
|